Clinical Trial

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

Caren Deardorf Editas Medicine, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer.CAMBRIDGE,…

1 year ago

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

PCT Examiner Finds Molecule to be both Novel and InventiveVANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech…

1 year ago

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed…

1 year ago

TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138

Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA…

1 year ago

Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company…

1 year ago

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

1 year ago

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

TORONTO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),…

1 year ago

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming…

1 year ago